Daniel J. Donovan
Independent DirectorMr. Daniel J. Donovan, also known as Dan, is Founder & Chief Executive officer of rareLife solutions, Inc. He Co-Founded Envision Pharma Ltd. in 2001 and served as its Managing Director, President and Principal until June 2011. He is Independent Director at Intensity Therapeutics, Inc. since January 2023. Mr. Donovan had been a Director at Cancer Prevention Pharmaceuticals, Inc. since November 2011 to June 2022. He had served as Chief Business Officer, a non-employee position, of Cancer Prevention Pharmaceuticals, Inc. from 2011 until immediately before the completion of its acquisition by Panbela in June 2022. He spent more than a decade in the pharmaceutical industry in both the U.S. and international markets, having held sales, market research and marketing positions of increasing responsibility. He then made the leap to the agency side of the business to gain insight into what makes a good agency tick, prior to founding Envision Pharma. At UBC Mr. Daniel Donovan was Senior Vice President Strategy and Market Development. He has done past work on both sides of the industry, he has been instrumental in supporting some of the most successful product launches in the industry through the development and implementation of innovative and creative solutions. Mr. Donovan has an intimate knowledge of the pharmaceutical industry and an understanding of the needs of medical and marketing teams. He finds great reward in helping his clients succeed, having learned from past work that success breeds success. He has served as Chief Executive Officer of rareLife Solutions, Inc. a private company since he co-founded it in 2014. He is Independent Director of Panbela Therapeutics, Inc. from June 15, 2022. He earned a Bachelor of Science degree in Finance at Lehigh University.
Positions
- Company NameIntensity Therapeutics, Inc.Stock CodeINTSPositionIndependent DirectorColleagues
- LHLewis H. BenderFounder, President, CEO & Chairman of the Board
- JTJoseph TalamoChief Financial Officer
- JWJohn WesolowskiPrincipal Accounting Officer & Controller
- JMJames M. AhlersExecutive Vice President of Corporate Finance
- ELEmer LeahyIndependent Director
- MAMark A. GoldbergIndependent Director
- RLRiccardo LencioniMember of Scientific Advisory Board
